*The Wearable Cardioverter-Defibrillator DOI: http://dx.doi.org/10.5772/intechopen.90663*

**Study description**

**70**

Erath et al. 102 WCD patients

Naniwadekar

patients

32% ICM, 46% NICM

85.9% Roger et al. 105 consecutive

Five patients (4.8%)

None

> patients with newly diagnosed ICM

or NICM and ejection fraction

≤35%

Sasaki et al. Nine patients at risk for

One patient (11.1%)

None

Median duration of use 21 days [7–

31]

Median wear time 23.7 h/day (23.6–

23.9)

SCD

Pediatric

Spar et al. 455 patients (age 3–

Six patients (1.3%) received a total

Two patients (0.4%)

Median duration of use 33 days (1–

Seven patients died, none of whom

were wearing the WCD at time of

death

999)

Median wear time 20.6 h/day (0.3–

23.8)

of 13 shocks

17 years) Psychological

Weiss et al. 123 WCD patients from

a multicenter several surveys

Registries

Chung et al. National postmarket

First shock success was 100%

(75/75) for unconscious

 VA and

Inappropriate

1.9% of patients in 4788 months of

use, or 1.4% per month

 shocks occurred in

Mean duration of wear

14.2% of patients

WCD

Overall survival rate was 99.2% but

discontinued

52.6

1590 days)

 69.9 days (range 1–

registry

Retrospective

 analysis

 registry

administered

NA

NA

NA (study followed patients for

Depressive

from 21% at baseline to 7% after

6 weeks of using the WCD

Anxiety decreased from 52% at

baseline to 25% at week 6

 symptoms decreased

> 6 weeks)

 aspects

African-Americans

 et al. 140 WCD

Two patients (1.4%) received a total

of two appropriate

 shocks

**Appropriate**

 Four patients (3.9%)

 **therapy**

**Inappropriate**

Two patients (2.0%), both due to

SVT

Two patients (1.4%) received a

total of four (two SVT, two artifacts)

inappropriate

 shocks

83 days)

Mean daily wear time 17.3

day

Mean duration of wear

At the end of WCD wear, 54.8% of

ICM and 48.8% of NICM patients

indicated for primary prevention

ICD

One patient died of worsening heart

failure

67% received an ICD

68.8

Mean wear time 21.5

 3.5 h/day

 50.4 days

 7.5 h/

 **therapy**

**Wear time** Median duration 54 days Median daily wear 23 h/day Median duration 43 days (7–

Seven patients died

*Sudden Cardiac Death*

32% received an ICD

**Comments**

55% received an ICD


**Study description**

**73**

Infected device removal (11.4%)

and others Feldman et al.

Eight appropriate

75% were successful

The two

unsuccessful

 shocks were

 shocks of which

Six

inappropriate

unnecessary

shocks/month)

 shocks (0.67%

Mean duration of use was

12 patients died

(5 of whom were not wearing WCD,

and 1 wore it improperly) 68 patients dropped out of study for

*The Wearable Cardioverter-Defibrillator DOI: http://dx.doi.org/10.5772/intechopen.90663*

> adverse events or discomfort

wearing the WCD

3.1 months (2.6 for BIROAD and

3.4 for WEARIT groups,

respectively)

Daily wear time not reported

WEARIT (n = 177) and BIROAD

(n = 112) studies

WEARIT patients had

heart failure and ejection fraction <

30%

BIROAD patients had acute

myocardial

waiting period of 30–40 days before an ICD could be implanted Wassnig et al. 6043 WCD patients

 94 patients (1.6%) were shocked

26 patients (0.4%), incidence 2.3

Median duration varied from 49 to

Patients with explanted ICDs had

higher average rates of shock (19.3

per 100

29.0)

patient-years,

 95% CI, 12.2–

66 days Median daily wear varied from 22.7

to 23.5 h/day

(95% CI, 1.5–3.4) per 100 patient-

Incidence rate 8.5% (95% CI, 6.7–

10.7) per 100

and 7.9% (95% CI, 4.8–12.3) for

women

94% success rate One patient (0.94%) shocked for

Two patients (1.9%)

Median duration of wear 58.5 days

17% various reasons: discomfort,

frequent alarms,

problems, technical issues

reimbursement

discontinued

 therapy for

> Mean wear time 22.7 h/day

Younger patients (≤ 50 years) less

compliant

12.3% had an average of >1

inappropriate

day (shocks aborted)

*cardiomyopathy;*

 *SCA, sudden cardiac arrest; SCD, sudden cardiac death; SVT,* 

*cardioverter-defibrillator.*

 *EP,* 

*electrophysiologist;*

 *ICD, implantable*

*supraventricular*

 *tachycardia;*

 *VA, ventricular arrhythmia;*

*cardioverter-defibrillator;*

 *ICM, ischemic* 

*cardiomyopathy;*

 *NICM, nonischemic*

 *VF, ventricular fibrillation;*

 shock alarms per

VF, successful

Zylla et al. 106 real-life cases taken

from 2010 to 2016 *AMI, acute myocardial infarction; CI, confidence interval; CM,* 

*cardiomyopathy;*

*VT, ventricular tachycardia;*

**Table 1.**

*An overview of the main uses of the WCD, therapy deliveries, and key findings [15, 17–44].*

 *NYHA, New York Heart Association;*

 *WCD, wearable* 

patient-years

 for men

years

In 10 cases, the reason was SVT

 infarction and were in

symptomatic

deemed related to improperly

placed electrodes

**Appropriate**

 **therapy**

**Inappropriate**

patients, no

delivered

inappropriate

 shocks

 **therapy**

**Wear time**

**Comments**


#### **Table 1.**

*An* 

 *overview of the main uses of the WCD, therapy deliveries, and key findings [15, 17–44].*
